When added to standard chemotherapy, a clinical version of the dietary supplement L-glutamine improved survival in an early-phase trial of patients with advanced pancreatic cancer. The study, led by Cedars-Sinai Health Sciences University investigators, was published in Nature Cancer.
L-glutamine Supplement Enhances Survival in Advanced Pancreatic Cancer Patients
A clinical trial led by Cedars-Sinai Health Sciences University showed that adding L-glutamine to standard chemotherapy improved survival rates for patients with advanced pancreatic cancer. This research, published in Nature Cancer, highlights advancements in cancer treatment. The implications for Iran could involve potential access to new treatment options for cancer patients.
👥 Key Players
📰 What Happened
A clinical trial found that adding L-glutamine to standard chemotherapy improved survival rates for patients with advanced pancreatic cancer. This research was published in the journal Nature Cancer.
- The study showed significant improvements in patient survival rates.
- L-glutamine is a dietary supplement that is being tested for its efficacy in cancer treatment.
💡 Why It Matters
📚 Background
Pancreatic cancer is one of the most lethal forms of cancer, and new treatment options are crucial for improving patient outcomes. L-glutamine is being researched for its potential benefits in enhancing chemotherapy effectiveness.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%